{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:39:13Z","timestamp":1790959153513,"version":"4.1.0"},"reference-count":209,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T00:00:00Z","timestamp":1602115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.574271","type":"journal-article","created":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T10:00:12Z","timestamp":1602151212000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":182,"title":["The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?"],"prefix":"10.3389","volume":"11","author":[{"given":"Rossana","family":"Franzin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Stefano","family":"Netti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Spadaccino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camillo","family":"Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loreto","family":"Gesualdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Stallone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ranieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,10,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI83871","article-title":"Cancer immunotherapy: harnessing the immune system to battle cancer","volume":"125","author":"Yang","year":"2015","journal-title":"J Clin Invest"},{"key":"B2","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br J Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2174\/1574886313666180508122332","article-title":"Musculoskeletal and Rheumatic Diseases Induced by Immune Checkpoint Inhibitors: A Review of the Literature","volume":"13","author":"Benfaremo","year":"2018","journal-title":"Curr Drug Saf"},{"key":"B5","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.kint.2019.07.022","article-title":"Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do","volume":"97","author":"Perazella","year":"2020","journal-title":"Kidney Int"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study","volume":"31","author":"Cortazar","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1126\/science.1131078","article-title":"Reversal of the TCR stop signal by CTLA-4","volume":"313","author":"Schneider","year":"2006","journal-title":"Science"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(00)80284-8","article-title":"Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement","volume":"6","author":"Perez","year":"1997","journal-title":"Immunity"},{"key":"B9","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/s0960-9822(02)00506-7","article-title":"Lymphocyte activation: T-cell regulation by CTLA-4","volume":"6","author":"Linsley","year":"1996","journal-title":"Curr Biol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/328267a0","article-title":"A new member of the immunoglobulin superfamily\u2013CTLA-4","volume":"328","author":"Brunet","year":"1987","journal-title":"Nature"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1126\/science.1160062","article-title":"CTLA-4 control over Foxp3+ regulatory T cell function","volume":"322","author":"Wing","year":"2008","journal-title":"Science"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(00)80406-9","article-title":"Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells","volume":"7","author":"Chambers","year":"1997","journal-title":"Immunity"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.19.1.565","article-title":"CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy","volume":"19","author":"Chambers","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1084\/jem.190.3.355","article-title":"Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte\/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied","volume":"190","author":"van Elsas","year":"1999","journal-title":"J Exp Med"},{"key":"B16","article-title":"Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade","volume":"60","author":"Hurwitz","year":"2000","journal-title":"Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 pathway in tolerance and autoimmunity","volume":"236","author":"Francisco","year":"2010","journal-title":"Immunol Rev"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nm1517","article-title":"Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma","volume":"13","author":"Parsa","year":"2007","journal-title":"Nat Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"key":"B23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000437178","article-title":"Immune Checkpoint Inhibitors","volume":"42","author":"Haanen","year":"2015","journal-title":"Prog Tumor Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13045-018-0592-6","article-title":"Gut microbiome modulates efficacy of immune checkpoint inhibitors","volume":"11","author":"Yi","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e1249561","DOI":"10.1080\/2162402X.2016.1249561","article-title":"Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer","volume":"6","author":"Huang","year":"2017","journal-title":"Oncoimmunology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","article-title":"Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4","volume":"18","author":"Qin","year":"2019","journal-title":"Mol Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1084\/jem.171.5.1393","article-title":"LAG-3, a novel lymphocyte activation gene closely related to CD4","volume":"171","author":"Triebel","year":"1990","journal-title":"J Exp Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0150","article-title":"Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells","volume":"3","author":"Kouo","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1126\/science.aah3374","article-title":"Pathological alpha-synuclein transmission initiated by binding lymphocyte-activation gene 3","volume":"353","author":"Mao","year":"2016","journal-title":"Science"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20100637","article-title":"Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients","volume":"207","author":"Fourcade","year":"2010","journal-title":"J Exp Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat Commun"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.03.050","article-title":"A soluble LAG-3 protein as an immunopotentiator for therapeutic vaccines: Preclinical evaluation of IMP321","volume":"24","author":"Fougeray","year":"2006","journal-title":"Vaccine"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2019.1629239","article-title":"Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy","volume":"11","author":"Yu","year":"2019","journal-title":"MAbs"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-Related Adverse Events Associated with Immune Checkpoint Blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/ced.13867","article-title":"Vitiligo-like depigmentation in oncology patients treated with immunotherapies for nonmelanoma metastatic cancers","volume":"44","author":"Liu","year":"2019","journal-title":"Clin Exp Dermatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0237","article-title":"Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1\/PD-L1 Inhibitors in Cancer Patients","volume":"5","author":"De Velasco","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2018050488","article-title":"Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future","volume":"29","author":"Perazella","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfy105","article-title":"Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis","volume":"34","author":"Manohar","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00990119","article-title":"The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors","volume":"14","author":"Seethapathy","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e192535","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1159\/000455014","article-title":"Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review","volume":"45","author":"Wanchoo","year":"2017","journal-title":"Am J Nephrol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.358","article-title":"Acute interstitial nephritis related to immune checkpoint inhibitors","volume":"115","author":"Belliere","year":"2016","journal-title":"Br J Cancer"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0478-8","article-title":"Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience","volume":"7","author":"Mamlouk","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1177\/1758835919875549","article-title":"The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma","volume":"11","author":"Marco","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2017.2","article-title":"Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup","volume":"13","author":"Chawla","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-016-1327-z","article-title":"Impact of acute kidney injury defined by CTCAE v4.0 during first course of cisplatin-based chemotherapy on treatment outcomes in advanced urothelial cancer patients","volume":"21","author":"Ishitsuka","year":"2017","journal-title":"Clin Exp Nephrol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27969","article-title":"Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma","volume":"119","author":"Weber","year":"2013","journal-title":"Cancer"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfy100","article-title":"Renal toxicities associated with pembrolizumab","volume":"12","author":"Izzedine","year":"2019","journal-title":"Clin Kidney J"},{"key":"B52","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s40425-016-0171-8","article-title":"Antitumor activity of nivolumab on hemodialysis after renal allograft rejection","volume":"4","author":"Ong","year":"2016","journal-title":"J Immunother Cancer"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/iju.13420","article-title":"Successful treatment of metastatic clear cell carcinoma with nivolumab in a patient receiving dialysis treatment","volume":"24","author":"Tabei","year":"2017","journal-title":"Int J Urol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2016.02.057","article-title":"Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients","volume":"68","author":"Shirali","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"B55","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.kint.2015.11.028","article-title":"Ipilimumab-associated minimal-change disease","volume":"89","author":"Kidd","year":"2016","journal-title":"Kidney Int"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-014-0092-7","article-title":"Kidney injuries related to ipilimumab","volume":"32","author":"Izzedine","year":"2014","journal-title":"Invest New Drugs"},{"key":"B57","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/his.13064","article-title":"Drug-induced nephropathies","volume":"70","author":"Paueksakon","year":"2017","journal-title":"Histopathology"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2017.04.026","article-title":"Nephrotic Syndrome With Cancer Immunotherapies: A Report of 2 Cases","volume":"70","author":"Kitchlu","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000189","article-title":"Nivolumab-associated Nephrotic Syndrome in a Patient With Renal Cell Carcinoma: A Case Report","volume":"40","author":"Daanen","year":"2017","journal-title":"J Immunother"},{"key":"B60","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12882-016-0408-2","article-title":"Nivolumab-associated acute glomerulonephritis: a case report and literature review","volume":"17","author":"Jung","year":"2016","journal-title":"BMC Nephrol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3345\/kjp.2016.59.5.205","article-title":"Shin J Il. Pathogenesis of minimal change nephrotic syndrome: an immunological concept","volume":"59","author":"Kim","year":"2016","journal-title":"Korean J Pediatr"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2014.74","article-title":"A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use","volume":"86","author":"Blank","year":"2014","journal-title":"Kidney Int"},{"key":"B63","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1189\/jlb.1212621","article-title":"At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy","volume":"94","author":"Intlekofer","year":"2013","journal-title":"J Leukoc Biol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"key":"B67","doi-asserted-by":"publisher","first-page":"e0160221","DOI":"10.1371\/journal.pone.0160221","article-title":"Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports","volume":"11","author":"Abdel-Wahab","year":"2016","journal-title":"PLoS One"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0904283","article-title":"Anti-CTLA4 antibody-induced lupus nephritis","volume":"361","author":"Fadel","year":"2009","journal-title":"N Engl J Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant Myocarditis with Combination Immune Checkpoint Blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2006.06.009","article-title":"T cells with low avidity for a tissue-restricted antigen routinely evade central and peripheral tolerance and cause autoimmunity","volume":"25","author":"Zehn","year":"2006","journal-title":"Immunity"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2015.12.005","article-title":"Re-examining the Nature and Function of Self-Reactive T cells","volume":"37","author":"Richards","year":"2016","journal-title":"Trends Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2005.01.005","article-title":"PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesis","volume":"115","author":"Ding","year":"2005","journal-title":"Clin Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh423","article-title":"Suppressed T-cell activation by IFN-gamma-induced expression of PD-L1 on renal tubular epithelial cells","volume":"19","author":"Schoop","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2016.12.004","article-title":"Renal complications of immune checkpoint blockade","volume":"41","author":"Murakami","year":"2017","journal-title":"Curr Probl Cancer"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfw024","article-title":"Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma","volume":"9","author":"Murakami","year":"2016","journal-title":"Clin Kidney J"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1400497","article-title":"Both PD-1 ligands protect the kidney from ischemia reperfusion injury","volume":"194","author":"Jaworska","year":"2015","journal-title":"J Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2012010070","article-title":"Autocrine adenosine signaling promotes regulatory T cell-mediated renal protection","volume":"23","author":"Kinsey","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-018-0848-y","article-title":"Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report","volume":"19","author":"Koda","year":"2018","journal-title":"BMC Nephrol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.molimm.2008.09.015","article-title":"Dysfunctional DC subsets in RCC patients: ex vivo correction to yield an effective anti-cancer vaccine","volume":"46","author":"Gigante","year":"2009","journal-title":"Mol Immunol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/CJI.0000000000000236","article-title":"Cytokine Release Syndrome During Sequential Treatment With Immune Checkpoint Inhibitors and Kinase Inhibitors for Metastatic Melanoma","volume":"42","author":"Dimitriou","year":"2019","journal-title":"J Immunother"},{"key":"B81","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00345-014-1268-7","article-title":"Erratum to: Clinical and pathological outcomes of renal cell carcinoma (RCC) in native kidneys of patients with end-stage renal disease: a long-term comparative retrospective study with RCC diagnosed in the general population","volume":"33","author":"Breda","year":"2015","journal-title":"World J Urol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1592","article-title":"Spectrum of cancer risk among US solid organ transplant recipients","volume":"306","author":"Engels","year":"2011","journal-title":"JAMA"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15181","article-title":"Risk of lung cancer in lung transplant recipients in the United States","volume":"19","author":"Triplette","year":"2019","journal-title":"Am J Transplant"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042831","article-title":"Sirolimus for Kaposi\u2019s sarcoma in renal-transplant recipients","volume":"352","author":"Stallone","year":"2005","journal-title":"N Engl J Med"},{"key":"B85","article-title":"Evaluation of transplant candidates with pre-existing malignancies","volume":"2","author":"Penn","year":"1997","journal-title":"Ann Transplant"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfz026","article-title":"Pre-existing malignancies in renal transplant candidates-time to reconsider waiting times","volume":"34","author":"Watschinger","year":"2019","journal-title":"Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000002914","article-title":"Poor Outcomes with the Use of Checkpoint Inhibitors in Kidney Transplant Recipients","volume":"104","author":"Venkatachalam","year":"2019","journal-title":"Transplantation"},{"key":"B88","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/TP.0000000000000169","article-title":"Co-inhibitory pathways and their importance in immune regulation","volume":"98","author":"Murakami","year":"2014","journal-title":"Transplantation"},{"key":"B89","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.3390\/ijms20092194","article-title":"Programmed Cell Death 1 (PD-1) Inhibitors in Renal Transplant Patients with Advanced Cancer: A Double-Edged Sword","volume":"20","author":"Lai","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B90","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40425-016-0205-2","article-title":"Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor","volume":"5","author":"Escandon","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13711","article-title":"Checkpoint Inhibitors in Kidney Transplant Recipients and the Potential Risk of Rejection","volume":"16","author":"Alhamad","year":"2016","journal-title":"Am J Transplant"},{"key":"B92","doi-asserted-by":"publisher","first-page":"e291","DOI":"10.1097\/TP.0000000000001861","article-title":"Severe Allograft Rejection and Autoimmune Hemolytic Anemia After Anti-PD1 Therapy in a Kidney Transplanted Patient","volume":"101","author":"Deltombe","year":"2017","journal-title":"Transplantation"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13786","article-title":"Use of the PD-1 Pathway Inhibitor Nivolumab in a Renal Transplant Patient With Malignancy","volume":"16","author":"Boils","year":"2016","journal-title":"Am J Transplant"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1111\/tri.12834","article-title":"Mixed acute kidney allograft rejection after an antiprogrammed cell death protein 1 antibody treatment for lung epidermoid carcinoma","volume":"29","author":"Tamain","year":"2016","journal-title":"Transpl Int"},{"key":"B95","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1097\/TP.0b013e318211d342","article-title":"Sirolimus and proteinuria in renal transplant patients: evidence for a dose-dependent effect on slit diaphragm-associated proteins","volume":"91","author":"Stallone","year":"2011","journal-title":"Transplantation"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfv054","article-title":"Management and prevention of post-transplant malignancies in kidney transplant recipients","volume":"8","author":"Stallone","year":"2015","journal-title":"Clin Kidney J"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12795","article-title":"A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients","volume":"14","author":"Lim","year":"2014","journal-title":"Am J Transplant"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.6691","article-title":"Sirolimus for Secondary Prevention of Skin Cancer in Kidney Transplant Recipients: 5-Year Results","volume":"36","author":"Dantal","year":"2018","journal-title":"J Clin Oncol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g6679","article-title":"Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data","volume":"349","author":"Knoll","year":"2014","journal-title":"BMJ"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000184006.43152.8d","article-title":"Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies","volume":"80","author":"Kauffman","year":"2005","journal-title":"Transplantation"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1204166","article-title":"Sirolimus and secondary skin-cancer prevention in kidney transplantation","volume":"367","author":"Euvrard","year":"2012","journal-title":"N Engl J Med"},{"key":"B102","doi-asserted-by":"publisher","first-page":"755","DOI":"10.3390\/ijms20030755","article-title":"mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy","volume":"20","author":"Tian","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B103","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13045-019-0754-1","article-title":"Targeting mTOR for cancer therapy","volume":"12","author":"Hua","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2010.11.024","article-title":"An oscillatory switch in mTOR kinase activity sets regulatory T cell responsiveness","volume":"33","author":"Procaccini","year":"2010","journal-title":"Immunity"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12669","article-title":"Oscillatory mTOR inhibition and Treg increase in kidney transplantation","volume":"182","author":"Sabbatini","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31769","article-title":"Optimal oncologic management and mTOR inhibitor introduction are safe and improve survival in kidney and liver allograft recipients with de novo carcinoma","volume":"144","author":"Rousseau","year":"2019","journal-title":"Int J Cancer"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.10.5636","article-title":"Antagonistic roles for CTLA-4 and the mammalian target of rapamycin in the regulation of clonal anergy: enhanced cell cycle progression promotes recall antigen responsiveness","volume":"167","author":"Vanasek","year":"2001","journal-title":"J Immunol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2004.03.008","article-title":"Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease","volume":"41","author":"Longhi","year":"2004","journal-title":"J Hepatol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s12967-016-0916-7","article-title":"mTOR inhibitors effects on regulatory T cells and on dendritic cells","volume":"14","author":"Stallone","year":"2016","journal-title":"J Transl Med"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1614298","article-title":"Preserved Renal-Allograft Function and the PD-1 Pathway Inhibitor Nivolumab","volume":"376","author":"Barnett","year":"2017","journal-title":"N Engl J Med"},{"key":"B111","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.1038\/s41467-019-12628-1","article-title":"Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation","volume":"10","author":"Esfahani","year":"2019","journal-title":"Nat Commun"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2019.00119","article-title":"Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events","volume":"6","author":"Nakamura","year":"2019","journal-title":"Front Med"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30261-4","article-title":"Cancer immunotherapy efficacy and patients\u2019 sex: a systematic review and meta-analysis","volume":"19","author":"Conforti","year":"2018","journal-title":"Lancet Oncol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12967-018-1467-x","article-title":"Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade","volume":"16","author":"Valpione","year":"2018","journal-title":"J Transl Med"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N Engl J Med"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-15-3266-5_7","article-title":"Rational Discovery of Response Biomarkers: Candidate Prognostic Factors and Biomarkers for Checkpoint Inhibitor-Based Immunotherapy","volume":"1248","author":"Hou","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613493","article-title":"First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N Engl J Med"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1705692","article-title":"Cancer Immunotherapy Trials Not Immune from Imprecise Selection of Patients","volume":"376","author":"Garon","year":"2017","journal-title":"N Engl J Med"},{"key":"B122","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1080\/14737159.2019.1607729","article-title":"Metabolomic insights into pathophysiological mechanisms and biomarker discovery in clear cell renal cell carcinoma","volume":"19","author":"Lucarelli","year":"2019","journal-title":"Expert Rev Mol Diagn"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2412","article-title":"Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab","volume":"22","author":"Martens","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyy201","article-title":"Correlation between blood cell count and outcome of melanoma patients treated with anti-PD-1 antibodies","volume":"49","author":"Nakamura","year":"2019","journal-title":"Jpn J Clin Oncol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0127","article-title":"Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab","volume":"22","author":"Weide","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.23217","article-title":"Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors","volume":"8","author":"Diehl","year":"2017","journal-title":"Oncotarget"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20894","article-title":"Interleukin-23\/Th17 pathways and inflammatory bowel disease","volume":"15","author":"Abraham","year":"2009","journal-title":"Inflammation Bowel Dis"},{"key":"B128","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40425-015-0081-1","article-title":"Baseline circulating IL-17 predicts toxicity while TGF-beta1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma","volume":"3","author":"Tarhini","year":"2015","journal-title":"J Immunother Cancer"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-7-35","article-title":"CTLA4 blockade increases Th17 cells in patients with metastatic melanoma","volume":"7","author":"von Euw","year":"2009","journal-title":"J Transl Med"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2010.01157.x","article-title":"T helper 1, 2 and 17 cell subsets in renal transplant patients with delayed graft function","volume":"24","author":"Loverre","year":"2011","journal-title":"Transpl Int Off J Eur Soc Organ Transplant"},{"key":"B131","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.imlet.2016.08.002","article-title":"Systemic over-release of interleukin-17 in acute kidney injury after septic shock: Clinical and experimental evidence","volume":"178","author":"Maravitsa","year":"2016","journal-title":"Immunol Lett"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00147.2017","article-title":"Th17 cells contribute to pulmonary fibrosis and inflammation during chronic kidney disease progression after acute ischemia","volume":"314","author":"Mehrotra","year":"2018","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"38","DOI":"10.4048\/jbc.2019.22.e5","article-title":"Tumor-Associated Macrophages as Potential Prognostic Biomarkers of Invasive Breast Cancer","volume":"22","author":"Jeong","year":"2019","journal-title":"J Breast Cancer"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13157","article-title":"A possible interaction between periostin and CD163(+) skin-resident macrophages in pemphigus vulgaris and bullous pemphigoid","volume":"26","author":"Fujimura","year":"2017","journal-title":"Exp Dermatol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24509","article-title":"Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study","volume":"9","author":"Fujimura","year":"2018","journal-title":"Oncotarget"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2018.10.041","article-title":"M2 macrophages in kidney disease: biology, therapies, and perspectives","volume":"95","author":"Chen","year":"2019","journal-title":"Kidney Int"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2369-13-123","article-title":"Diagnostic value of urine sCD163 levels for sepsis and relevant acute kidney injury: a prospective study","volume":"13","author":"Su","year":"2012","journal-title":"BMC Nephrol"},{"key":"B138","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.clim.2019.06.005","article-title":"Urine macrophages reflect kidney macrophage content during acute tubular interstitial and glomerular injury","volume":"205","author":"Sun","year":"2019","journal-title":"Clin Immunol"},{"key":"B139","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1038\/s41598-020-58725-w","article-title":"M2 macrophages predict worse long-term outcomes in human acute tubular necrosis","volume":"10","author":"Kim","year":"2020","journal-title":"Sci Rep"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000701","article-title":"Treatment of immune checkpoint inhibitor-induced inflammatory arthritis","volume":"32","author":"Jeurling","year":"2020","journal-title":"Curr Opin Rheumatol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2016.12.019","article-title":"Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-alpha is a biomarker of nivolumab recativity","volume":"86","author":"Tanaka","year":"2017","journal-title":"J Dermatol Sci"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201602-0420CP","article-title":"Lung-Kidney Cross-Talk in the Critically Ill Patient","volume":"194","author":"Husain-Syed","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"B143","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/TP.0000000000001452","article-title":"Interleukin-6, A Cytokine Critical to Mediation of Inflammation, Autoimmunity and Allograft Rejection: Therapeutic Implications of IL-6 Receptor Blockade","volume":"101","author":"Jordan","year":"2017","journal-title":"Transplantation"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014080764","article-title":"Plasma IL-6 and IL-10 Concentrations Predict AKI and Long-Term Mortality in Adults after Cardiac Surgery","volume":"26","author":"Zhang","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B145","doi-asserted-by":"publisher","first-page":"R104","DOI":"10.1186\/cc7940","article-title":"Serum interleukin-6 and interleukin-8 are early biomarkers of acute kidney injury and predict prolonged mechanical ventilation in children undergoing cardiac surgery: a case-control study","volume":"13","author":"Liu","year":"2009","journal-title":"Crit Care"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.0994","article-title":"Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China","volume":"180","author":"Wu","year":"2020","journal-title":"JAMA Intern Med"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21409","article-title":"Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2009.04.016","article-title":"LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951)","volume":"45","author":"Agarwala","year":"2009","journal-title":"Eur J Cancer"},{"key":"B149","doi-asserted-by":"publisher","first-page":"e0166482","DOI":"10.1371\/journal.pone.0166482","article-title":"Prognostic Value of Serum Lactate Dehydrogenase in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis","volume":"11","author":"Shen","year":"2016","journal-title":"PLoS One"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt027","article-title":"Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival","volume":"24","author":"Delyon","year":"2013","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-014-1528-9","article-title":"Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma","volume":"63","author":"Kelderman","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.467","article-title":"Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma","volume":"114","author":"Diem","year":"2016","journal-title":"Br J Cancer"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.12030","article-title":"Predictive Factors for Poor Progression-free Survival in Patients with Non-small Cell Lung Cancer Treated with Nivolumab","volume":"37","author":"Taniguchi","year":"2017","journal-title":"Anticancer Res"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1039\/c5mb00492f","article-title":"Discovery of urinary metabolomic biomarkers for early detection of acute kidney injury","volume":"12","author":"Won","year":"2016","journal-title":"Mol Biosyst"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.4103\/1319-2442.168596","article-title":"Lactate dehydrogenase as a biomarker for early renal damage in patients with sickle cell disease","volume":"26","author":"Alzahri","year":"2015","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/18.3.543","article-title":"Measurement of tubular enzymuria facilitates early detection of acute renal impairment in the intensive care unit","volume":"18","author":"Westhuyzen","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2003.027763","article-title":"Prognostic value of tubular proteinuria and enzymuria in nonoliguric acute tubular necrosis","volume":"50","author":"Herget-Rosenthal","year":"2004","journal-title":"Clin Chem"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1007\/s10522-018-9771-7","article-title":"Reversing the immune ageing clock: lifestyle modifications and pharmacological interventions","volume":"19","author":"Duggal","year":"2018","journal-title":"Biogerontology"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2588","article-title":"Understanding immunosenescence to improve responses to vaccines","volume":"14","author":"Goronzy","year":"2013","journal-title":"Nat Immunol"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00734","article-title":"Inflammaging and Complement System: A Link Between Acute Kidney Injury and Chronic Graft Damage","volume":"11","author":"Franzin","year":"2020","journal-title":"Front Immunol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0177-9","article-title":"Can physical activity ameliorate immunosenescence and thereby reduce age-related multi-morbidity","volume":"19","author":"Duggal","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B162","doi-asserted-by":"publisher","first-page":"3422","DOI":"10.3390\/ijms21103422","article-title":"Molecular Mechanisms of Premature Aging in Hemodialysis: The Complex Interplay Between Innate and Adaptive Immune Dysfunction","volume":"21","author":"Losappio","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S165368","article-title":"The impact of immunosenescence on the efficacy of immune checkpoint inhibitors in melanoma patients: a meta-analysis","volume":"11","author":"Li","year":"2018","journal-title":"Onco Targets Ther"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31763","article-title":"Senescence markers: Predictive for response to checkpoint inhibitors","volume":"144","author":"Moreira","year":"2019","journal-title":"Int J Cancer"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4933-9-15","article-title":"Hallmarks of human \u201cimmunosenescence\u201d: adaptation or dysregulation","volume":"9","author":"Pawelec","year":"2012","journal-title":"Immun Ageing"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1038\/nature11824","article-title":"T-helper-1-cell cytokines drive cancer into senescence","volume":"494","author":"Braumuller","year":"2013","journal-title":"Nature"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e318167b023","article-title":"Interferon-alpha (IFN-alpha)-conditioned DC preferentially stimulate type-1 and limit Treg-type in vitro T-cell responses from RCC patients","volume":"31","author":"Gigante","year":"2008","journal-title":"J Immunother"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1080\/1354750X.2018.1493617","article-title":"Improving clinical prediction rules in acute kidney injury with the use of biomarkers of cell cycle arrest: a pilot study","volume":"24","author":"Hodgson","year":"2019","journal-title":"Biomarkers Biochem Indic Expo Response Susceptibility to Chem"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1016\/j.nefro.2017.11.013","article-title":"The use of cell cycle arrest biomarkers in the early detection of acute kidney injury. Is this the new renal troponin","volume":"38","author":"Ortega","year":"2018","journal-title":"Nefrologia"},{"key":"B171","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40635-016-0086-1","article-title":"Cross-species validation of cell cycle arrest markers for acute kidney injury in the rat during sepsis","volume":"4","author":"Peng","year":"2016","journal-title":"Intensive Care Med Exp"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccc.2019.08.010","article-title":"The Role of Biomarkers in Acute Kidney Injury","volume":"36","author":"Srisawat","year":"2020","journal-title":"Crit Care Clin"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000003907","article-title":"Use of Cell Cycle Arrest Biomarkers in Conjunction With Classical Markers of Acute Kidney Injury","volume":"47","author":"Joannidis","year":"2019","journal-title":"Crit Care Med"},{"key":"B174","doi-asserted-by":"publisher","first-page":"R25","DOI":"10.1186\/cc12503","article-title":"Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury","volume":"17","author":"Kashani","year":"2013","journal-title":"Crit Care"},{"key":"B175","doi-asserted-by":"publisher","first-page":"e1917","DOI":"10.1097\/MD.0000000000001917","article-title":"Soluble Serum \u03b1Klotho Is a Potential Predictive Marker of Disease Progression in Clear Cell Renal Cell Carcinoma","volume":"94","author":"Gigante","year":"2015","journal-title":"Med (Baltimore)"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2005.00846.x","article-title":"Increased expression of senescence-associated cell cycle inhibitor p16INK4a in deteriorating renal transplants and diseased native kidney","volume":"5","author":"Melk","year":"2005","journal-title":"Am J Transplant"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.18632\/aging.102059","article-title":"Complement component C5a induces aberrant epigenetic modifications in renal tubular epithelial cells accelerating senescence by Wnt4\/betacatenin signaling after ischemia\/reperfusion injury","volume":"11","author":"Castellano","year":"2019","journal-title":"Aging (Albany NY)"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13415","article-title":"Complement Modulation of Anti-Aging Factor Klotho in Ischemia\/Reperfusion Injury and Delayed Graft Function","volume":"16","author":"Castellano","year":"2016","journal-title":"Am J Transplant"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00328.2018","article-title":"Plasma and urinary p21: potential biomarkers of AKI and renal aging","volume":"315","author":"Johnson","year":"2018","journal-title":"Am J Physiol Renal Physiol"},{"key":"B180","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1159\/000484962","article-title":"Acute Kidney Injury to Chronic Kidney Disease Transition","volume":"193","author":"Fiorentino","year":"2018","journal-title":"Contrib Nephrol"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.01835","article-title":"The Human Gut Microbiome - A Potential Controller of Wellness and Disease","volume":"9","author":"Kho","year":"2018","journal-title":"Front Microbiol"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21398","article-title":"The role of the microbiome in cancer development and therapy","volume":"67","author":"Bhatt","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx108","article-title":"Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab","volume":"28","author":"Chaput","year":"2017","journal-title":"Ann Oncol"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao3290","article-title":"The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients","volume":"359","author":"Matson","year":"2018","journal-title":"Science"},{"key":"B185","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"B186","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.eururo.2020.04.044","article-title":"Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients","volume":"78","author":"Derosa","year":"2020","journal-title":"Eur Urol"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10391","article-title":"Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis","volume":"7","author":"Dubin","year":"2016","journal-title":"Nat Commun"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.01.003","article-title":"Manipulating the gut microbiome to decrease uremic toxins","volume":"91","author":"Yacoub","year":"2017","journal-title":"Kidney Int"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.02.011","article-title":"Evaluation of the impact of gut microbiota on uremic solute accumulation by a CE-TOFMS-based metabolomics approach","volume":"92","author":"Mishima","year":"2017","journal-title":"Kidney Int"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.2010.00882.x","article-title":"Role of indoxyl sulfate in the progression of chronic kidney disease and cardiovascular disease: experimental and clinical effects of oral sorbent AST-120","volume":"15","author":"Niwa","year":"2011","journal-title":"Ther Apher Dial"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1080\/08860220802356531","article-title":"AST-120 treatment in pre-dialysis period affects the prognosis in patients on hemodialysis","volume":"30","author":"Ueda","year":"2008","journal-title":"Ren Fail"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1159\/000363209","article-title":"Intestinal microbiota-kidney cross talk in acute kidney injury and chronic kidney disease","volume":"127","author":"Noel","year":"2014","journal-title":"Nephron Clin Pract"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1159\/000490392","article-title":"The Microbiome and Acute Kidney Injury","volume":"140","author":"Rabb","year":"2018","journal-title":"Nephron"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2020.4495","article-title":"Lactobacillus salivarius BP121 prevents cisplatininduced acute kidney injury by inhibition of uremic toxins such as indoxyl sulfate and pcresol sulfate via alleviating dysbiosis","volume":"45","author":"Lee","year":"2020","journal-title":"Int J Mol Med"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014030288","article-title":"Gut Bacteria Products Prevent AKI Induced by Ischemia-Reperfusion","volume":"26","author":"Andrade-Oliveira","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro2536","article-title":"Shifting the balance: antibiotic effects on host-microbiota mutualism","volume":"9","author":"Willing","year":"2011","journal-title":"Nat Rev Microbiol"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-017-0075-5","article-title":"Intergenerational transfer of antibiotic-perturbed microbiota enhances colitis in susceptible mice","volume":"3","author":"Schulfer","year":"2018","journal-title":"Nat Microbiol"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.90769.2008","article-title":"Early exposure to germs modifies kidney damage and inflammation after experimental ischemia-reperfusion injury","volume":"297","author":"Jang","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016030255","article-title":"Depletion of Gut Microbiota Protects against Renal Ischemia-Reperfusion Injury","volume":"28","author":"Emal","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30078-0","article-title":"Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis","volume":"19","author":"McQuade","year":"2018","journal-title":"Lancet Oncol"},{"key":"B201","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s11912-016-0539-4","article-title":"The Obesity Paradox in Cancer: a Review","volume":"18","author":"Lennon","year":"2016","journal-title":"Curr Oncol Rep"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30952-5","article-title":"Modulating the microbiome to improve therapeutic response in cancer","volume":"20","author":"McQuade","year":"2019","journal-title":"Lancet Oncol"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet (Lond Engl)"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.7150\/jca.24985","article-title":"Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan","volume":"9","author":"Lin","year":"2018","journal-title":"J Cancer"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01050","article-title":"Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences","volume":"9","author":"Yan","year":"2018","journal-title":"Front Pharmacol"},{"key":"B208","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2019.10.006","article-title":"Lactate up-regulates the expression of PD-L1 in kidney and causes immunosuppression in septic Acute Renal Injury","author":"Xu","year":"2019","journal-title":"J Microbiol Immunol Infect"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.574271\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T10:00:15Z","timestamp":1602151215000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.574271\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,8]]},"references-count":209,"alternative-id":["10.3389\/fimmu.2020.574271"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.574271","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,8]]},"article-number":"574271"}}